Blade Therapeutics

Blade Therapeutics appoints Dr. Maria E. Fuentes EVP, Research

Tuesday, August 22, 2017

Blade Therapeutics, a private biopharmaceutical company advancing novel anti-fibrotic therapies to meet important patient needs, announced the appointment of Maria E. Fuentes, Ph.D., as Executive Vice President, Research. In this newly established position, Dr. Fuentes will lead Blade’s anti-fibrotic programs in preclinical testing. Blade’s flagship program, focused on a small molecule cysteine protease inhibitor, is expected to enter IND-enabling studies by year-end 2017.

[Read More]